Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.

Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T.

Nature. 2012 Oct 18;490(7420):412-6. doi: 10.1038/nature11538. Epub 2012 Oct 10.

PMID:
23051752
2.

Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA.

J Immunol. 1996 Jan 15;156(2):700-10.

PMID:
8543823
3.

Cancer therapy: Tumours switch to resist.

Ribas A, Tumeh PC.

Nature. 2012 Oct 18;490(7420):347-8. doi: 10.1038/nature11489. Epub 2012 Oct 10. No abstract available.

4.

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.

Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH.

Cancer Immunol Immunother. 2000 Mar;48(12):661-72.

PMID:
10752474
5.

Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.

Sutmuller RP, Schurmans LR, van Duivenvoorde LM, Tine JA, van Der Voort EI, Toes RE, Melief CJ, Jager MJ, Offringa R.

J Immunol. 2000 Dec 15;165(12):7308-15.

7.

Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.

Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, Somerville R, Wunderlich JR, Sherry RM, Yang JC, Rosenberg SA, Kammula US.

Clin Cancer Res. 2015 Feb 1;21(3):534-43. doi: 10.1158/1078-0432.CCR-14-2208. Epub 2014 Nov 25.

8.

T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.

Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA.

Cancer J. 2000 Mar-Apr;6(2):69-77.

PMID:
11069222
9.

Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?

Auphan-Anezin N, Verdeil G, Grange M, Soudja SM, Wehbe M, Buferne M, Mas A, Schmitt-Verhulst AM.

Pigment Cell Melanoma Res. 2013 Mar;26(2):167-75. doi: 10.1111/pcmr.12056. Epub 2012 Dec 27.

PMID:
23217139
10.

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J, Kosmider N, White K, Stern H, Soglia J, Adams J, Palombella VJ, McGovern K, Kutok JL, Wolchok JD, Merghoub T.

Nature. 2016 Nov 17;539(7629):443-447. doi: 10.1038/nature20554. Epub 2016 Nov 9.

PMID:
27828943
11.

Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.

Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA.

Cancer Res. 1995 Nov 1;55(21):4972-9.

12.

Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens.

Saleh FH, Crotty KA, Hersey P, Menzies SW, Rahman W.

J Pathol. 2003 Jul;200(3):383-95. Retraction in: J Pathol. 2006 Nov;210(3):383.

PMID:
12845635
13.

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.

Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, Schmidt T, Hornung V, Davidson I, Goding CR, Jönsson G, Landsberg J, Tüting T, Hölzel M.

Nat Commun. 2015 Nov 4;6:8755. doi: 10.1038/ncomms9755.

14.

Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma.

Gottlieb DJ, Li YC, Lionello I, Tanzarella S, Marangolo M, Bradstock KF, Russo V, Traversari C.

Br J Cancer. 2006 Jul 17;95(2):181-8. Epub 2006 Jul 4.

15.

Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.

Voelkl S, Moore TV, Rehli M, Nishimura MI, Mackensen A, Fischer K.

Cancer Immunol Immunother. 2009 May;58(5):709-18. doi: 10.1007/s00262-008-0593-3. Epub 2008 Oct 3.

17.
18.

Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy.

Wagner SN, Wagner C, Schultewolter T, Goos M.

Cancer Immunol Immunother. 1997 Jun;44(4):239-47.

PMID:
9222283
19.

Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.

Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P.

Clin Cancer Res. 2006 Oct 1;12(19):5801-8.

20.

T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.

Straetemans T, Coccoris M, Berrevoets C, Treffers-Westerlaken E, Scholten CE, Schipper D, Ten Hagen TL, Debets R.

Hum Gene Ther. 2012 Feb;23(2):187-201. doi: 10.1089/hum.2010.126. Epub 2011 Dec 2.

PMID:
21958294

Supplemental Content

Support Center